{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:16:36Z","timestamp":1719965796028},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>The aim was to investigate MAGE-A4 and MAGE-A1 protein expression in high-grade endometrial cancer and determine its correlation with histologic subtype, FIGO stage, presence of vascular invasion, disease free, and overall survival. Immunohistochemical staining was performed by using 77B (MAGE-A1) and 57B (MAGE-A4) monoclonal antibodies on paraffin-embedded sections from high-grade endometrial cancers diagnosed in University Hospital Split between 1998 and 2011 (n=77). Median follow-up time for survivors was 48\u2009mo. MAGE-A4 was found to be expressed in 33% of endometrioid type endometrial cancers grade 3 and in 27% of serous and clear cell carcinomas. MAGE-A1 was found to be expressed in 93% endometrioid endometrial cancer grade 3 and 86% of serous and clear cell carcinomas. Univariate analysis showed that positive immunohistochemical staining for MAGE-A4 was associated with decreased disease free and overall survival in patients with high-grade endometrial cancer. Multivariate analysis showed an association between MAGE-A4 overexpression and decreased disease free but not overall survival in high-grade endometrial cancer. No correlation was found between MAGE-A1 immunohistochemical expression and patient survival. There was no significant correlation between MAGE-A4 and MAGE-A1 expression and histologic subtype, FIGO stage, lymph node metastasis, muscular infiltration, and lymphovascular invasion. MAGE-A4 immunohistochemical expression is associated with decreased disease free and overall survival in patients with high-grade endometrial cancer. Our findings suggest that MAGE-A1 may be expressed in the epithelial cells of the normal endometrium. MAGE-A1 is highly expressed in high-grade endometrial cancer, with no impact on survival.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000470","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T18:40:02Z","timestamp":1510684802000},"page":"59-65","source":"Crossref","is-referenced-by-count":5,"title":["MAGE-A4 and MAGE-A1 Immunohistochemical Expression in High-grade Endometrial Cancer"],"prefix":"10.1097","volume":"38","author":[{"given":"Sanja","family":"Srdeli\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Kuzmi\u0107-Prusac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio C.","family":"Spagnoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Jureti\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vesna","family":"\u010capkun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230824","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"8","author":"Simpson","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"R2-20230824","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"van der Bruggen","year":"1991","journal-title":"Science"},{"key":"R3-20230824","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1084\/jem.182.3.689","article-title":"A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma","volume":"182","author":"Van den Eynde","year":"1995","journal-title":"J Exp Med"},{"key":"R4-20230824","first-page":"1","article-title":"The cancer\/testis genes: review, standardization, and commentary","volume":"23","author":"Scanlan","year":"2004","journal-title":"Cancer Immun"},{"key":"R5-20230824","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1006\/jsre.2001.6148","article-title":"NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma","volume":"98","author":"Goydos","year":"2001","journal-title":"J Surg Res"},{"key":"R6-20230824","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ijc.2910630313","article-title":"Expression of MAGE genes in primary and metastatic cutaneous melanoma","volume":"63","author":"Brasseur","year":"1995","journal-title":"Int J Cancer"},{"key":"R7-20230824","first-page":"1549","article-title":"MAGE-3 immunoreactivity in formalin-fixed, paraffin embedded primary and metastatic melanoma: frequency and distribution","volume":"151","author":"Hofbauer","year":"1997","journal-title":"Am J Pathol"},{"key":"R8-20230824","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.1158\/1078-0432.CCR-05-1203","article-title":"Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer","volume":"11","author":"Gure","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R9-20230824","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0304-3835(99)00385-7","article-title":"Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9","volume":"150","author":"Scanlan","year":"2000","journal-title":"Cancer Lett"},{"key":"R10-20230824","first-page":"177","article-title":"The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention","volume":"4","author":"Domagala-Kulawik","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"R11-20230824","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2051-1426-3-S2-O19","article-title":"(2003) Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer","volume":"3","author":"Sharma","year":"2003","journal-title":"Cancer Immun"},{"key":"R12-20230824","first-page":"4671","article-title":"Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade","volume":"61","author":"Kurashige","year":"2001","journal-title":"Cancer Res"},{"key":"R13-20230824","doi-asserted-by":"crossref","first-page":"e104099","DOI":"10.1371\/journal.pone.0104099","article-title":"Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer","volume":"9","author":"Daudi","year":"2014","journal-title":"PLoS One"},{"key":"R14-20230824","doi-asserted-by":"crossref","first-page":"10668","DOI":"10.1074\/jbc.M206104200","article-title":"MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity","volume":"278","author":"Nagao","year":"2003","journal-title":"J Biol Chem"},{"key":"R15-20230824","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1084\/jem.187.8.1349","article-title":"A survey of the humoral immune response of cancer patients to a panel of human tumor antigens","volume":"187","author":"Stockert","year":"1998","journal-title":"J Exp Med"},{"key":"R16-20230824","doi-asserted-by":"crossref","first-page":"11810","DOI":"10.1073\/pnas.92.25.11810","article-title":"Human neoplasms elicit multiple specific immune responses in the autologous host","volume":"92","author":"Sahin","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R17-20230824","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/j.1349-7006.2009.01303.x","article-title":"Cancer\/testis (CT) antigens: potential targets for immunotherapy","volume":"100","author":"Caballero","year":"2009","journal-title":"Cancer Sci"},{"key":"R18-20230824","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1200\/JCO.2012.43.7111","article-title":"Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma","volume":"31","author":"Kruit","year":"2013","journal-title":"J Clin Oncol"},{"key":"R19-20230824","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1200\/JCO.2012.43.7103","article-title":"Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results","volume":"31","author":"Vansteenkiste","year":"2013","journal-title":"J Clin Oncol"},{"key":"R20-20230824","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.18632\/oncotarget.1834","article-title":"Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus","volume":"5","author":"Piha-Paul","year":"2014","journal-title":"Oncotarget"},{"key":"R21-20230824","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1158\/1078-0432.CCR-12-1158","article-title":"Phase I study of the antiangiogenic antibody bevacizumab and the mTOR\/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity","volume":"18","author":"Moroney","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R22-20230824","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3802\/jgo.2008.19.3.157","article-title":"Present status and future direction of clinical trials in advanced endometrial carcinoma","volume":"19","author":"Homesley","year":"2008","journal-title":"J Gynecol Oncol"},{"key":"R23-20230824","doi-asserted-by":"crossref","first-page":"218.e1","DOI":"10.1016\/j.ajog.2007.08.075","article-title":"Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths","volume":"198","author":"Ueda","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"R24-20230824","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ijc.10585","article-title":"Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas","volume":"101","author":"Resnick","year":"2002","journal-title":"Int J Cancer"},{"key":"R25-20230824","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/modpathol.3800232","article-title":"Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray","volume":"18","author":"Chitale","year":"2005","journal-title":"Mod Pathol"},{"key":"R28-20230824","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ygyno.2003.08.018","article-title":"Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases","volume":"91","author":"Slomovitz","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R30-20230824","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/ijc.25777","article-title":"MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies","volume":"129","author":"Schultz-Thater","year":"2011","journal-title":"Int J Cancer"},{"key":"R31-20230824","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/(SICI)1097-0215(20000215)85:4<460::AID-IJC3>3.0.CO;2-N","article-title":"Expression of MAGE-antigens in normal tissues and cancer","volume":"85","author":"Jungbluth","year":"2000","journal-title":"Int J Cancer"},{"key":"R32-20230824","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1471-2407-12-169","article-title":"Lipocalin 2 expression is associated with aggressive features of endometrial cancer","volume":"12","author":"Mannelqvist","year":"2012","journal-title":"BMC Cancer"},{"key":"R33-20230824","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/his.12633","article-title":"Lipocalin-2 and matrix metalloproteinase-9 expression in high-grade endometrial cancer and their prognostic value","volume":"67","author":"Srdeli\u0107 Mihalj","year":"2015","journal-title":"Histopathology"},{"key":"R34-20230824","first-page":"6453","article-title":"Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms","volume":"9","author":"Yakirevich","year":"2003","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00004347-201901000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T01:47:45Z","timestamp":1692841665000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004347-201901000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000470","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}